Use of oxytocin and misoprostol for induction or ... - POPPHI

More documents

Recommendations

Info

misoprostol for obstetric doses of 25mcg for induction, as well as 400-600mcg for AMTSL should be made available in all LRS settings. 7. Non-pharmacological methods of induction should be explored for use at health center level for non-urgent and elective inductions as they are inexpensive, require little monitoring and have been shown through systematic reviews to pose little risk to mother and baby. 5
Acronyms ACOG AMRN AMTSL CS EFM FDA FIGO HRS ICM IOL IUFD IUGR LDC LRS MDC PATH POPPHI RCOG SOGC WHO American College of Obstetricians and Gynecologists African Midwives Research Network Active management of third stage of labor Cesarean section Electronic fetal monitoring US Federal Drug Administration Federation International de Gynecologie et Obstetrics High resource setting International Confederation of Midwives Induction of labor Intra-uterine fetal demise Intra-uterine growth retardation Less developed country Low resource setting More developed country Programs for appropriate technologies in health Prevention of post partum hemorrhage initiative Royal College of Obstetricians and Gynecologists Society of Obstetricians and Gynecologists of Canada World Health Organization 6
Page 1 and 2: Use of oxytocin and misoprostol for
Page 3 and 4: data from lower level and private f
Page 5: the literature provides us with ver
Page 9 and 10: List of Tables Table 1.1a Published
Page 11 and 12: 1. Introduction Low and middle inco
Page 13 and 14: Comment Setting Country Source and
Page 15 and 16: 4) To summarize current rates, tren
Page 17 and 18: eview given its focus on the use of
Page 19 and 20: Category Inclusion Exclusion Ration
Page 21 and 22: Table 3.1a provides definitions for
Page 23 and 24: Prerequisite clinical conditions fo
Page 25 and 26: practitioner’s discretion as outl
Page 27 and 28: Table 3.3c WHO recommendations for
Page 29 and 30: Table 3.4a National induction rates
Page 31 and 32: variable induction rates in Washing
Page 33 and 34: Table 3.4c: The percent distributio
Page 35 and 36: studies that assessed this outcome.
Page 37 and 38: 3.5 Rates, Trends, Indications and
Page 39 and 40: Tables 3.5b presents rates of induc
Page 41 and 42: Table 3.5d Hospital-specific rates
Page 43 and 44: adverse outcomes of induction becau
Page 45 and 46: this is not associated with increas
Page 47 and 48: use in LRS, particularly given the
Page 49 and 50: Sweeping of the membranes was compa
Page 51 and 52: concern regarding its use for early
Page 53 and 54: Misoprostol is now available in som
Page 55 and 56: Figure 3.6 c World map showing glob
Page 57 and 58:
documented rates of elective induct
Page 59 and 60:
In general, definitions, descriptio
Page 61 and 62:
An evidence-based safe and effectiv
Page 63 and 64:
Appendix A: Glossary of common term
Page 65 and 66:
References 1. World Health Organiza
Page 67 and 68:
28. Beebe LA, Rayburn WF, Beaty CM,
Page 69 and 70:
55. Maternity statistics, england:
Page 71 and 72:
81. Roberts CL, Algert CS, Douglas
Page 73:
105. Nigam A, Singh VK, Dubay P, Pa
show all

Use of oxytocin and misoprostol for induction or ... - POPPHI

Create successful ePaper yourself

Delete template?

Save as template?